Clinical trial
Instillation of Gemcitabine in Patients With Superficial Bladder Cancer
NCT00191477 · Eli Lilly and Company, Industry · Terminated
Key facts
| NCT number | NCT00191477 |
|---|---|
| Title | Instillation of Gemcitabine in Patients With Superficial Bladder Cancer |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bladder Neoplasms |
| Intervention type | Drug |
| Interventions | Gemcitabine, Placebo |
| Enrollment | 355 |
| Start date | Jan 1, 2004 |
| Primary completion | Mar 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 28, 2009 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: